TNGX financials
Tango Therapeutics (TNGX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
TNGX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $62.38M | $60.10M | -$111.29M | -$101.59M | -0.87 |
| 2024 | $42.07M | $42.07M | -$145.59M | -$130.30M | -1.19 |
| 2023 | $36.53M | $36.53M | -$114.17M | -$101.74M | -1.08 |
| 2022 | $24.86M | $24.86M | -$111.07M | -$108.18M | -1.23 |
| 2021 | $37.04M | $37.04M | -$58.19M | -$58.23M | -0.94 |
| 2020 | $7.66M | $6.03M | -$52.20M | -$51.97M | -1.62 |
- TNGX revenue was $62.38M in fiscal 2025, net income -$101.59M.
Updated 2026-11-07 11:56 UTC